ERBB2 and neoplasm: The included studies evaluated various clinicopathological parameters, such as tumor size (≤2 cm vs. >2 cm), histological grade (1–2 vs. 3), lymph node metastasis, ER status, PR status, HER-2 status, Ki-67 labeling index, and molecular subtype (non-TNBC vs. TNBC).